抗疟药物耐药性：将恶性疟原虫生物学与临床联系起来
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
作者信息
Blasco Benjamin, Leroy Didier, Fidock David A
机构信息
Medicines for Malaria Venture, Geneva, Switzerland.
Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
出版信息
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
摘要
21世纪初基于青蒿素的联合疗法（ACTs）在全球范围内的采用开创了有效治疗耐药恶性疟原虫疟疾的新纪元。然而，现在几个东南亚国家报告称出现了对青蒿素（ART）衍生物和ACT联合用药敏感性降低的寄生虫，导致治疗失败率不断上升。在此，我们回顾了在理解抗疟药物的作用方式以及耐药性如何产生方面的最新进展，并讨论了有效对抗耐药性、优化治疗以及推进全球疟疾消除运动的新策略。
相似文献
1
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.抗疟药物耐药性：将恶性疟原虫生物学与临床联系起来
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
2
How genomics is contributing to the fight against artemisinin-resistant malaria parasites.基因组学如何助力对抗青蒿素耐药疟原虫。
Acta Trop. 2015 Aug;148:1-7. doi: 10.1016/j.actatropica.2015.04.007. Epub 2015 Apr 21.
3
Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.恶性疟原虫对青蒿素联合疗法的耐药性：疟疾消除之路上的达摩克利斯之剑。
Parasite. 2018;25:24. doi: 10.1051/parasite/2018021. Epub 2018 Apr 20.
4
Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure.青蒿素长期压力诱导恶性疟原虫产生多药耐受性。
Emerg Infect Dis. 2015 Oct;21(10):1733-41. doi: 10.3201/eid2110.150682.
5
Artemisinin-Resistant Plasmodium falciparum Malaria.抗青蒿素疟原虫疟疾。
Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0013-2016.
6
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?三药联合疗法治疗疟疾——一种新模式？
Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12.
7
Artemisinin derivatives and malaria: useful, in combination with other antimalarials.青蒿素衍生物与疟疾：与其他抗疟药物联合使用时有效。
Prescrire Int. 2008 Aug;17(96):162-8.
8
Antimalarial drug resistance in Africa: the calm before the storm?非洲的抗疟药物耐药性：暴风雨前的平静？
Lancet Infect Dis. 2019 Oct;19(10):e338-e351. doi: 10.1016/S1473-3099(19)30261-0. Epub 2019 Jul 30.
9
Artemisinin Action and Resistance in Plasmodium falciparum.青蒿素在恶性疟原虫中的作用与耐药性
Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9.
10
Artemisinin resistance in Plasmodium falciparum: what is it really?疟原虫对青蒿素的抗药性：它到底是什么？
Trends Parasitol. 2013 Jul;29(7):318-20. doi: 10.1016/j.pt.2013.05.002. Epub 2013 Jun 11.
引用本文的文献
1
Novel Inhibitors of Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and Efficacy in a Humanized Mouse Malaria Infection Model.新型磷脂酰肌醇4激酶IIIβ抑制剂，耐药倾向低：在人源化小鼠疟疾感染模型中的生命周期阶段活性和疗效
J Med Chem. 2025 Aug 28;68(16):17736-17751. doi: 10.1021/acs.jmedchem.5c01417. Epub 2025 Aug 14.
2
Antimalarial activity of root extract of Tephrosia villosa L. Pers. (Fabaceae) on Plasmodium berghei-infected mice.绒毛灰叶（豆科）根提取物对感染伯氏疟原虫小鼠的抗疟活性。
Sci Rep. 2025 Jul 25;15(1):27162. doi: 10.1038/s41598-025-11137-0.
3
Direct long-read visualization reveals hidden variation in GCH1 gene copy number and precise expansion steps.直接长读长可视化揭示了GCH1基因拷贝数的隐藏变异和精确的扩增步骤。
BMC Genomics. 2025 Jul 17;26(1):671. doi: 10.1186/s12864-025-11859-5.
4
Comprehensive genomic study of Plasmodium falciparum in Sierra leone: genetic variation and resistance patterns.塞拉利昂恶性疟原虫的综合基因组研究：遗传变异与抗药模式
BMC Genomics. 2025 Jul 1;26(1):584. doi: 10.1186/s12864-025-11771-y.
5
Malaria: past, present, and future.疟疾：过去、现在与未来。
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
6
A comprehensive review of cerebral malaria.脑型疟疾的全面综述。
J Parasit Dis. 2025 Jun;49(2):257-272. doi: 10.1007/s12639-024-01758-z. Epub 2024 Nov 15.
7
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.撒哈拉以南非洲疟疾感染人群中恶性疟原虫K13基因对青蒿素联合疗法及相关药物的新出现突变
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
8
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.重新利用抗疟药：乙胺嘧啶在体外对加德纳菌的活性优于甲硝唑，同时对乳酸杆菌无损害。
J Antimicrob Chemother. 2025 Jul 1;80(7):1972-1979. doi: 10.1093/jac/dkaf157.
9
The fast-evolving FIKK kinase family of Plasmodium falciparum can be inhibited by a single compound.恶性疟原虫快速进化的FIKK激酶家族可被单一化合物抑制。
Nat Microbiol. 2025 May 19. doi: 10.1038/s41564-025-02017-4.
10
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria.ATM激酶抑制剂AZD0156是疟原虫磷脂酰肌醇4激酶（PI4Kβ）的强效抑制剂，是抗疟疾药物化学优化的有吸引力的候选物。
Angew Chem Int Ed Engl. 2025 Jul 7;64(28):e202425206. doi: 10.1002/anie.202425206. Epub 2025 May 15.
本文引用的文献
1
Protein Degradation Systems as Antimalarial Therapeutic Targets.蛋白质降解系统作为抗疟治疗靶点
Trends Parasitol. 2017 Sep;33(9):731-743. doi: 10.1016/j.pt.2017.05.009. Epub 2017 Jul 5.
2
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.一种基于四氧杂环烷的抗疟药物候选物，可克服 PfK13-C580Y 依赖性青蒿素耐药性。
Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.
3
A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine.一种变异的疟原虫氯喹抗性转运蛋白（PfCRT）异构体可能导致对一线联合用药磷酸哌喹产生耐药性。
mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
4
Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons.疟疾与青蒿素联合疗法中的氧化应激：利弊
FEBS J. 2017 Aug;284(16):2579-2591. doi: 10.1111/febs.14097. Epub 2017 May 25.
5
Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase.磷脂酰肌醇4激酶抑制剂MMV390048的抗疟疗效
Sci Transl Med. 2017 Apr 26;9(387). doi: 10.1126/scitranslmed.aad9735.
6
K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness .K13突变对臭氧敏感性和寄生虫适应性有不同影响。
mBio. 2017 Apr 11;8(2):e00172-17. doi: 10.1128/mBio.00172-17.
7
Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis.葡萄糖-6-磷酸脱氢酶缺乏与疟疾的关系：系统评价和荟萃分析。
Sci Rep. 2017 Apr 6;7:45963. doi: 10.1038/srep45963.
8
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.新型长效抗疟药DSM265的安全性、耐受性、药代动力学及活性：一项分为两部分的首次人体1a/1b期随机研究
Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.
9
Targeting the Parasite to Suppress Malaria Transmission.靶向寄生虫以抑制疟疾传播。
Adv Parasitol. 2017;97:147-185. doi: 10.1016/bs.apar.2016.09.004. Epub 2016 Nov 12.
10
Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis.甲氟喹靶向疟原虫 80S 核糖体以抑制蛋白质合成。
Nat Microbiol. 2017 Mar 13;2:17031. doi: 10.1038/nmicrobiol.2017.31.
Zotero 插件